Home›Research›Compare›AICAR vs Cagrilintide
Peptide ComparisonAICAR vs Cagrilintide
Both are Metabolic peptides.
Cagrilintide
AM833
Half-life: ~7 days
20 providers listed
Cagrilintide carries stronger published evidence (Meta-analysis, 10 key studies) than AICAR (RCT, 12); both are research compounds.
AICAR
Evidence
Half-life
—
Cagrilintide
Evidence
Half-life
~7 days
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | Cagrilintide |
| Lower typical price per mg | AICAR |
| More provider options (3 vs 20) | Cagrilintide |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
AICAR
Cagrilintide
AICAR
Targeting AMPK Networks for Male Reproductive Health: Mechanisms and Emerging Therapies.
Thapsigargin-induced autophagic flux impairment and inflammation are potentiated by CLN3 deficiency and allev…
The AMPK-PGC-1α-SIRT3 axis mediates mitochondrial metabolic dysfunction and neuronal senescence induced by Al…
Berberine Regulates Hepatic Fatty Acid Metabolism via AMPK/SIRT1/PGC-1α Pathway.
+8 more
Cagrilintide
Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A N…
Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with o…
Combination of cagrilintide and semaglutide 2·4 mg for weight management in adults with overweight and obesit…
Cagrilintide 2·4 mg once-weekly subcutaneous injection in adults with overweight or obesity (SCALE-CAGRI): a…
+6 more
About AICAR
Converted intracellularly to ZMP, a potent AMPK activator. AMPK activation increases fatty acid oxidation, glucose uptake, and mitochondrial biogenesis — the same metabolic pathways activated by sustained aerobic exercise.
About Cagrilintide
Long-acting amylin analogue; acts on amylin/calcitonin receptors to prolong satiety; synergistic with semaglutide in CagriSema combination
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
AICAR
No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.
Cagrilintide
Under clinical review
Being verified by our medical team before we display contraindications for this peptide.
Given mechanistic overlap with GLP-1 agonists when used as CagriSema, monitor thyroid C-cell markers (calcitonin), lipase for pancreatitis risk, and a baseline metabolic panel. Amylin-specific monitoring guidance is evolving as Phase 3 data matures; follow prescribing protocol of the co-administered agent.
AICAR
Cagrilintide
Where to source these peptides
AICAR
3 listed
Browse directory →
Providers offeringCagrilintide
20 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Metabolic Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated July 27, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). AICAR vs Cagrilintide — Per-mg Price Comparison. Retrieved July 29, 2026, from https://peptidebase.io/peptides/compare/aicar/cagrilintide